Amgen Expands Puerto Rico Biologics Facility With Additional $300M Investment Amid Tariff Pressure

Amgen ($AMGN) is investing an additional $300 million to expand its biologics manufacturing facility in Puerto Rico, bringing its recent commitments to the site to nearly $1 billion as drugmakers increase U.S. production capacity amid evolving tariff policies.

• The $300 million expansion targets Amgen’s Juncos, Puerto Rico facility, a key global production hub serving more than 60 countries.
• The investment builds on a previously announced $650 million upgrade at the same site.
• Amgen’s total U.S. investment commitments over the past year are approaching $2 billion.
• The expansion is expected to support advanced manufacturing roles and create hundreds of construction jobs.
• The Juncos facility, established in 1992, includes more than 20 buildings and employs thousands of workers.
• Amgen has also announced a $900 million Ohio manufacturing expansion and a $600 million R&D center in California.
• Pharmaceutical companies have increased domestic investment following U.S. tariff policies targeting imported branded drugs.
• Amgen is among companies that have entered drug-pricing agreements with the U.S. government, providing tariff relief.
• According to recent lobbying disclosures, the company has engaged on issues related to drug pricing, trade, and manufacturing policy.

Relevant Companies

• Amgen ($AMGN) – Expanding U.S. manufacturing capacity and navigating tariff and drug pricing policies.
• Novartis ($NVS) – Also increasing U.S. manufacturing investments as part of a broader industry trend.

Editor’s Note: This is a developing story. This article may be updated as more details become available.